Article in Annals of the American Thoracic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03506061 (iPS Cell Response to CFTR Modulators), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTR
TypeinterventionalSponsorEmory UniversityRan2019 to 2024Enrolled42ConditionsCystic FibrosisArmsTrikafta
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Rachel W LinnemannDepartment of Pediatrics, Emory University, Atlanta, GA, United States.ORCID 0000-0002-6839-0936
George M SolomonDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0002-2969-5518
Adrianna L WestbrookDepartment of Pediatrics, Emory University, Atlanta, GA, United States.ORCID 0000-0001-9309-6205
Rachel RichDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Ashleigh StrebyDepartment of Pediatrics, Emory University, Atlanta, GA, United States.
Eric HunterDepartment of Pediatrics, Emory University, Atlanta, GA, United States.
Andras RabDepartment of Pediatrics, Emory University, Atlanta, GA, United States.ORCID 0000-0003-2154-0017
Shasha BaiDepartment of Pediatrics, Emory University, Atlanta, GA, United States.ORCID 0000-0003-4999-327X
Carmel M McNicholasDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0002-7013-8764
Jeong S HongDepartment of Pediatrics, Emory University, Atlanta, GA, United States.
Candela ManfrediDepartment of Pediatrics, Emory University, Atlanta, GA, United States.
William R HuntDepartment of Medicine, Emory University, Atlanta, GA, United States.ORCID 0000-0002-1882-7132
Arlene A StecenkoDepartment of Pediatrics, Emory University, Atlanta, GA, United States.ORCID 0000-0001-7800-3031
Cristina BarillàInstitute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, United States.ORCID 0000-0002-7169-8528
Shingo SuzukiInstitute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, United States.ORCID 0000-0001-7034-7120
Brian R DavisInstitute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, United States.ORCID 0000-0001-8020-8212
Eric J SorscherDepartment of Pediatrics, Emory University, Atlanta, GA, United States.ORCID 0000-0001-9341-3354
Funding
UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0M
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicineR01HL139876 · NHLBI · EMORY UNIVERSITY · PI DAVIS, BRIAN R., SORSCHER, ERIC J · 2018 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Elexacaftor-tezacaftor-ivacaftor for individuals with residual CFTR activity: an open-label, nonrandomized clinical trial. · full record | OpenQuestion